Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses

Abstract excerpt

Interleukin-10 (IL-10)-producing group 2 innate lymphoid cells (ILC2 10 ) regulate inflammatory immune responses, yet their therapeutic potential remains largely unexplored. Here, we demonstrate that cell therapy with human ILC2 10 inhibits pathogenic T cell responses in humanized mouse models of graft-versus-host disease (GVHD), resulting in reduced GVHD severity and improved overall survival without limiting...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to IL-33, ST2, and ILC Pathways
• Share to Immune Cell Function and Interaction
• Share to Xenotransplantation and immune response